Suchergebnisse - "Croes, Sander"

PubPharm (62)

1

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC

enthalten in: JTO clinical and research reports | 2024

von Gulikers, J. | Veerman, G. | Jebbink, M. | +12

2

Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer

enthalten in: International journal of cancer | 2024

von van Veelen, A. | Veerman, G. | Verschueren, M. | +15

3

Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs

enthalten in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences | 2023

von Kruithof, P. | de Beer, Y. | Gulikers, J. | +4

4

Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer : real-world outcomes versus clinical trial results

enthalten in: Immunotherapy | 2023

von Verschueren, M. | Dijs, T. | Gulikers, J. | +8

5

Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma

enthalten in: Biomedical chromatography : BMC | 2023

von Gulikers, J. | van Veelen, A. | Sinkiewicz, E. | +7

6

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

enthalten in: Targeted oncology | 2023

von Ter Heine, R. | van den Heuvel, M. | Piet, B. | +17

7

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib

enthalten in: JTO clinical and research reports | 2023

von Brouns, A. | van Veelen, A. | Veerman, G. | +6

8

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

enthalten in: EClinicalMedicine | 2023

von Veerman, G. | Boosman, R. | Jebbink, M. | +14

9

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

enthalten in: Targeted oncology | 2023

von ter Heine, R. | van den Heuvel, M. | Piet, B. | +17

10

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients : Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

enthalten in: Frontiers in oncology | 2023

von Meertens, M. | Muntinghe-Wagenaar, M. | Sikkema, B. | +19

1
2
3
4
5
6
7
Nächster »
[7]